Bicycle Therapeutics (BCYC) Projected to Post Earnings on Tuesday

Bicycle Therapeutics (NASDAQ:BCYC) will likely be releasing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Bicycle Therapeutics to post earnings of ($1.00) per share and revenue of $7.0760 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 2:00 AM ET.

Bicycle Therapeutics Stock Performance

BCYC stock opened at $5.37 on Monday. The company has a market cap of $372.52 million, a price-to-earnings ratio of -1.48 and a beta of 1.63. The business’s 50-day moving average is $6.44 and its two-hundred day moving average is $7.03. Bicycle Therapeutics has a fifty-two week low of $5.03 and a fifty-two week high of $12.60.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BCYC. Truist Financial assumed coverage on shares of Bicycle Therapeutics in a research note on Monday, November 24th. They issued a “hold” rating and a $10.00 price objective on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $11.00 target price (down from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Citizens Jmp set a $12.00 price target on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Jefferies Financial Group upgraded Bicycle Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 17th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.11.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 10,989 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $6.46, for a total value of $70,988.94. Following the completion of the transaction, the chief executive officer owned 618,996 shares of the company’s stock, valued at $3,998,714.16. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Alethia Young sold 4,334 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the sale, the chief financial officer directly owned 87,081 shares in the company, valued at $565,155.69. This trade represents a 4.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 38,029 shares of company stock valued at $251,966 in the last ninety days. 8.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. GSK plc purchased a new position in shares of Bicycle Therapeutics in the fourth quarter worth $10,829,000. Schroder Investment Management Group bought a new stake in Bicycle Therapeutics in the 4th quarter valued at $3,976,000. Woodline Partners LP purchased a new stake in Bicycle Therapeutics in the 1st quarter worth $3,088,000. Birchview Capital LP boosted its holdings in shares of Bicycle Therapeutics by 200.5% during the 4th quarter. Birchview Capital LP now owns 462,700 shares of the company’s stock valued at $3,276,000 after purchasing an additional 308,700 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Bicycle Therapeutics by 156.5% during the 1st quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock valued at $3,850,000 after purchasing an additional 276,671 shares during the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.